Piribo: New Report on the Women's Health Pharmaceutical Market to 2011

Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has just added to its collection a key market report entitled The Women's Health Market Outlook to 2011 (http://www.piribo.com/search/results.html?k=rbi130&x=0&y=0). This new 224 page report provides analysis of the current and future market for women's health drugs across all major indications osteoporosis, infertility, uterine fibroids, endometriosis, urinary incontinence and gynaecological infections.

(PRWEB) May 11, 2007 -- Piribo, the online destination for business intelligence for the biotech and pharmaceutical industry, has just added to its collection a key market report entitled The Women's Health Market Outlook to 2011 (http://www.piribo.com/search/results.html?k=rbi130&x=0&y=0). This new 224 page report provides analysis of the current and future market for women's health drugs across all major indications osteoporosis, infertility, uterine fibroids, endometriosis, urinary incontinence and gynaecological infections.

Key findings of this new report include:

- The leading hormonal contraceptive brand in 2005 was Schering AG's Yasmin which accrued $666m in sales.

- GSK's Boniva (ibandronate) indicated for the treatment of osteoporosis is forecast to accrue $1,309m by the end of the forecast period in 2011.

- Although Merck held the leading position among competing companies in the WH market in 2005, its marketed franchise comprises of a lone product, Fosamax, with an indication in osteoporosis Fosamax and its reformulated counter part Fosamax PLUS D which accrued combined sales of $2,845m in 2005.

This report, published by Datamonitor and available from Piribo.com, will help the reader forecast sales of the major products in the women's health sector and evaluate the potential market share of leading companies.

The report, with 25 figures and 65 tables, contains profiles of major companies operating in this fast moving area, including Akzo Nobel/Organon, Barr, Bayer-Schering Pharma, Johnson & Johnson, Merck, Novartis, Pfizer, Procter & Gamble, Watson and Wyeth. The following are examined for each company; sales focus by drug class, marketed product portfolio, R&D pipeline and growth potential.

Content in brief

- Executive Summary

- Chapter 1 Epidemiology of Women's Health

- Chapter 2 Global market analysis

- Chapter 3 Pipeline analysis

- Chapter 4 Competitive landscape

- Chapter 5 Appendix

"The Women's Health Market Outlook to 2011" is available from Piribo priced at £1,495. For more information, go to: http://www.piribo.com/publications/therapeutic/womens_health_market_2011.html

About Piribo.

Piribo is a UK-based independent online store supplying business information on the pharmaceutical and biotechnology industries. The website now carries over 6,000 English language titles including, market reports, studies and books and is the UK's largest online biopharma information store. Subscribers receive a free monthly newsletter and email alerts on new titles in their areas of interest. The company was established in 2004.

###